Investigation of the clinical potential of ESCM has been limited, largely due to the significant risk associated with the use of G-CSF, the main stem cell mobilizer used in clinical trial, for extended periods of time (Bensinger et al., 1996; Shimoda et al., 1993).
Recently, a new stem cell mobilizer (StemEnhance® SE) has been developed that triggers a much milder increase in the number of PBSC, but its safety allows for a sustained oral daily consumption over long periods of time, allowing for safe daily ESCM (Jensen et al., 2007).

In brief, SE is an extract from the cyanophyta Aphanizomenon flos-aquae that concentrates a protein with an estimated molecular weight of 160-180 kDa, which was shown to be a selective L-selectin blocker.
Oral consumption of 1 gram of SE was been shown to trigger an average 25% increase in the number of PBSC within 60 minutes after consumption. The magnitude of the mobilization induced by SE is much smaller than that triggered by G-CSF, however its safety allows for continuous use and therefore offers a novel approach in the study of ESCM.

To test its therapeutic potential, SE was used in a number of preliminary clinical trials involving a number of diagnostic entities.

Christian Drapeau,a member of Gitte Jensen, Ph.D, research team that created the patented Stem Enhance ULTRA